Wilms' tumor (WT1) gene expression is increased in patients with leukemia as well as myelodysplastic syndrome (MDS) and is useful for detection of minimal residual disease (MRD). A 47-year-old man given a diagnosis of refractory anemia with excess of blasts in transformation (RAEB-T) received myeloablative therapy followed by autologous peripheral blood stem cell transplantation (PBSCT). MRD by WT1 expression was not detected in the graft. The patient has been in CR for 25 months after PBSCT. These observations suggest that PBSCT is feasible for patients with RAEB-T and analysis of WT1 expression can be applied for patients with high risk MDS. Keywords: autologous peripheral blood stem cell transplantation; myelodysplastic syndrome; WT1 gene expression The Wilms' tumor gene (WT1 gene), which acts as a tumor suppressor of Wilms' tumor and as a transcription factor for several growth and differentiation factors, is expressed in blast cells of acute leukemia and measurement of the WT1 level is useful for detecting MRD in acute leukemia. Recently, it has been demonstrated that WT1 gene expression is detectable in the blasts of MDS at diagnosis and that the level is significantly increased in patients with RAEB and RAEB-T.
The Wilms' tumor gene (WT1 gene), which acts as a tumor suppressor of Wilms' tumor and as a transcription factor for several growth and differentiation factors, is expressed in blast cells of acute leukemia and measurement of the WT1 level is useful for detecting MRD in acute leukemia. 1 Recently, it has been demonstrated that WT1 gene expression is detectable in the blasts of MDS at diagnosis and that the level is significantly increased in patients with RAEB and RAEB-T. 2 Myelodysplastic syndrome (MDS) represents clonal proliferation and maturation of hematopoietic stem cells, and is classified into five categories. Two of these, refractory anemia with excess of blasts (RAEB) and RAEB in transformation (RAEB-T), are associated with a high risk of developing acute leukemia. Such patients are usually treated with conventional chemotherapy but the results are unsatisfactory.
Allogeneic bone marrow transplantation (BMT) is a curative therapy for young patients with an HLA-matched donor. Autologous peripheral blood stem cell transplantation (PBSCT) is considered to be an alternative approach for elderly patients or those who lack a suitable donor. 3 We report a case of successful autologous PBSCT for MDS (RAEB-T), and discuss the usefulness of WT-1 expression to detect minimal residual disease (MRD) in grafts.
Case report
A 46-year-old man was admitted to our hospital in July 1995 due to general malaise and weight loss. Hematological examination on admission showed hematocrit of 35.0%, white blood cells of 8.7 × 10 9 /l with 4% blasts, and platelets of 178 × 10 9 /l. Bone marrow examination revealed normocellularity with 8.8% blasts. Trilineage myelodysplastic changes were observed in the bone marrow, and Auer rods were seen in some blasts. No chromosomal abnormality specific to MDS was seen. The patient was given a diagnosis of RAEB-T and was treated with combined chemotherapy with cytosine arabinoside (CA) and idarubicin as induction therapy. Complete remisson (CR) was achieved. Three courses of consolidation chemotherapy were given consecutively. The patient had no HLA-identical siblings and was considered to be in a high risk group for unrelated BMT. He was therefore treated with high-dose chemotherapy with autologous PBSCT. In January 1996, he received high dose CA (3 g/m 2 , every 12 h for 2 days) followed by recombinant human (rh) G-CSF for PBSC mobilization, and PBSC were harvested during hematopoietic recovery. The details of PBSC mobilization, cryopreservation and transplantation have been previously described. 3 2.64 × 10 6 /kg CD34 + cells were obtained after 3 courses of PBSC mobilization. In November 1996, he received myeloablative conditioning with busulfan and cyclophosphamide followed by autologous PBSCT. A total of 2.23 × 10 6 /kg CD34 + cells was infused for 3 days. He was given rh G-CSF at a dose of 50 g/m 2 subcutanously from day 1 until the number of neutrophils exceeded 1 × 10 9 /l. The times needed to reach 0.5 × 10 9 /l neutrophils and 50 × 10 9 /l platelets were 12 and 20 days, respectively. Transient thrombocytopenia occurred between 6 and 12 weeks after PBSCT, probably induced by an autoimmune mechanism. 4 He has been in CR for 25 months after PBSCT.
Analysis of the WT1 gene in the graft
To detect MRD of RAEB-T in the graft, the level of WT1 gene in the graft was examined by competitive reverse transcription-polymerase chain reaction (RT-PCR) as previously described. 5 Briefly, a standard of WT1 mRNA was prepared by using WT1 primers. After total RNA prepared from the patient was mixed with a standard WT1 mRNA, RT-PCR was performed with 40 cycles. WT1 mRNA from the patient competed with a standard WT1 mRNA. After electrophoresis, ethidium bromide staining was performed and bands were identified (Figure 1 ). Densitometric analysis was employed to determine the WT1 mRNA concentration for quantitation. The same procedure was performed using mRNA of ␤-actin and the value of WT1 gene expression was compensated with that of ␤-actin gene expression to normalize differences in RNA degradation for the sample. Thus, the amounts of RNA in the sample were calculated. The amounts of WT1 mRNA in the PBSC product were less than 1 × 10 copies/g RNA, suggesting that MRD was not detected in the graft.
Discussion
Allogeneic BMT can produce 40-50% long-term diseasefree survival in patients with a high risk of MDS under the age of 50. 6 Autologous hematopoietic stem cell transplantation is an alternative therapy for patients who lack an HLA-compatible donor. De Witte et al 7 reported that the 2-year survival and disease-free survival for 19 patients who received allogeneic BMT in the first CR were 46% and 40%, respectively. However, few patients have received autologous PBSCT in high-risk MDS. 8 We describe a case of successful autologous PBSCT for REAB-T. The patient showed rapid hematological recovery as has been seen in acute myelogenous leukemia (AML) 3 and has been in CR for 25 months.
One disadvantage of autologous PBSCT is the possible contamination of the graft by tumor cells, which may result in relapse of the disease. 9 Carella et al 10 reported that karyotypically normal PBSC could be mobilized in patients with high risk MDS. However, in patients with normal karyotypes, contaminating leukemia cells could not be identified in the graft.
The level of WT1 gene expression is significantly increased in patients with RAEB and RAEB-T and the quantitation of WT1 gene expression is useful for detection of MRD in MDS. 2 In the present case, we analyzed the expression of WT1 in the PBSC graft and demonstrated no increase in WT1 levels, which suggested that normal PBSC could be harvested without contamination by RAEB-T blast cells. These observations suggest that PBSCT is feasible and useful for patients with high risk MDS who lack an HLA-matched allogeneic donor and that analysis of WT1 expression can be used for patients with high risk MDS who lack specific clonal markers. Further analyses and prospective studies are required to clarify our findings.
